Merck & Co., Inc. (NYSE:MRK) Releases FY 2022 Earnings Guidance

Merck & Co., Inc. (NYSE:MRKGet Rating) updated its FY 2022 earnings guidance on Monday. The company provided earnings per share (EPS) guidance of $7.24-$7.36 for the period, compared to the consensus estimate of $7.24. The company issued revenue guidance of $56.90 billion-$58.10 billion, compared to the consensus revenue estimate of $57.35 billion.

Several brokerages have issued reports on MRK. StockNews.com began coverage on shares of Merck & Co., Inc. in a research report on Thursday, March 31st. They set a strong-buy rating on the stock. Barclays raised their price objective on shares of Merck & Co., Inc. from $94.00 to $97.00 and gave the stock an overweight rating in a research report on Tuesday, April 12th. SVB Leerink lowered their price objective on shares of Merck & Co., Inc. from $100.00 to $97.00 and set an outperform rating on the stock in a research report on Thursday, April 21st. JPMorgan Chase & Co. lowered their price objective on shares of Merck & Co., Inc. from $100.00 to $95.00 and set an overweight rating on the stock in a research report on Friday, January 28th. Finally, Morgan Stanley lowered their price objective on shares of Merck & Co., Inc. from $82.00 to $80.00 and set an equal weight rating on the stock in a research report on Wednesday, April 6th. Eight equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, Merck & Co., Inc. has a consensus rating of Buy and a consensus price target of $90.69.

Merck & Co., Inc. stock traded up $0.79 during trading on Tuesday, reaching $88.43. The company had a trading volume of 136,939 shares, compared to its average volume of 12,126,637. The company has a debt-to-equity ratio of 0.80, a quick ratio of 1.02 and a current ratio of 1.27. Merck & Co., Inc. has a 12-month low of $70.89 and a 12-month high of $91.40. The stock’s 50 day moving average price is $82.99 and its two-hundred day moving average price is $80.47. The firm has a market capitalization of $223.53 billion, a price-to-earnings ratio of 15.68, a PEG ratio of 1.19 and a beta of 0.37.

Merck & Co., Inc. (NYSE:MRKGet Rating) last released its quarterly earnings data on Thursday, April 28th. The company reported $2.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.83 by $0.31. Merck & Co., Inc. had a net margin of 26.27% and a return on equity of 49.57%. The company had revenue of $15.90 billion during the quarter, compared to the consensus estimate of $14.64 billion. During the same period in the previous year, the firm earned $1.40 earnings per share. Merck & Co., Inc.’s revenue for the quarter was up 31.6% on a year-over-year basis. As a group, research analysts expect that Merck & Co., Inc. will post 7.31 earnings per share for the current year.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Morgan Stanley lifted its position in shares of Merck & Co., Inc. by 17.1% during the second quarter. Morgan Stanley now owns 26,289,496 shares of the company’s stock worth $2,044,534,000 after purchasing an additional 3,832,086 shares in the last quarter. Heritage Wealth Advisors lifted its position in shares of Merck & Co., Inc. by 8.4% during the fourth quarter. Heritage Wealth Advisors now owns 297,246 shares of the company’s stock worth $22,781,000 after purchasing an additional 23,053 shares in the last quarter. Privium Fund Management UK Ltd acquired a new stake in Merck & Co., Inc. in the fourth quarter valued at $8,729,000. Marshall Wace LLP raised its holdings in Merck & Co., Inc. by 176.2% in the fourth quarter. Marshall Wace LLP now owns 39,087 shares of the company’s stock valued at $2,996,000 after acquiring an additional 90,373 shares in the last quarter. Finally, EP Wealth Advisors LLC increased its stake in Merck & Co., Inc. by 5.1% during the fourth quarter. EP Wealth Advisors LLC now owns 23,985 shares of the company’s stock valued at $1,838,000 after purchasing an additional 1,173 shares during the last quarter. 72.88% of the stock is currently owned by institutional investors and hedge funds.

About Merck & Co., Inc. (Get Rating)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines.

Further Reading

Earnings History and Estimates for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.